Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 4 1Phase 2 1

Status

Unknown 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 79Triple Negative Breast Neoplasms 9Stomach Neoplasms 8Inflammatory Breast Neoplasms 6Carcinoma, Hepatocellular 6Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Sarcoma 2Primary Breast Cancer 2Pathologic Complete Response 2Lung Neoplasms 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Nasopharyngeal Carcinoma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Mitomycin 12Gemcitabine 9BCG Vaccine 4apaziquone 3Epirubicin 3erdafitinib 2durvalumab 2dodecyl maltoside 2VB4-845 2Docetaxel 2viscum album peptide 1valrubicin 1pirarubicin 1hydroxycamptothecinum 1Transurethral Resection of Bladder 1Therapeutic Uses 1Standard of Care 1Saline Solution 1Radiotherapy 1Polysorbates 1Maintenance 1Magnetic Resonance Spectroscopy 1Injections 1Cystoscopy 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Non-Muscle Invasive Bladder Neoplasms × Epirubicin × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04490993 2022-02-22

ACCRUE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 3 Unknown
359 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04736394 2022-02-22

ASCERTAIN

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 3 Unknown
800 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡